- Home
- Clinical Care
- Medication handovers: why a shared list needs a shared explanation
Medication handovers: why a shared list needs a shared explanation
Safer transitions of care
The most consequential document at hospital discharge may look ordinary: a list of medicines. Yet its value depends on whether the next clinician, the pharmacist and the person going home understand the same plan. A list can be complete on screen while leaving a practical question unanswered at the kitchen table.
Medication reconciliation addresses that gap between records and real use. It deserves attention whenever responsibility for care changes, including admission, ward transfer and discharge. For professionals, the task combines accurate information with a clear account of what changed and who will resolve remaining uncertainties.
Begin with what the person actually takes
The Agency for Healthcare Research and Quality describes reconciliation as comparing a patient's existing regimen with admission, transfer or discharge orders, then discussing discrepancies with the prescriber. The comparison should lead to resolution where necessary, rather than simply producing another version of the record.
AHRQ's MATCH toolkit includes prescription medicines and products that can be overlooked: nonprescription treatments, vitamins, supplements, eye drops, creams and herbal preparations. Its approach also calls for an updated list at discharge and clear responsibilities for the staff collecting and confirming information.
Consider an illustrative workflow problem: a record contains one dose, a dispensing label shows another and the patient describes taking something different. None of those observations alone explains why. The useful next step is to clarify the discrepancy with the responsible professional and document the agreed plan, not silently select whichever entry looks newest.
Explain the changes, not just the names
The World Health Organization's 2019 report identifies transitions of care as a priority for medication safety. It places structured processes alongside workforce capability, patient and family partnership, information quality and measurement. That combination matters because a reliable handover involves people and systems, rather than a form acting alone.
Graymedy's editorial interpretation is that a discharge conversation should make the story of the list visible. Which medicines continue? Which were added, stopped or changed? What is the reason, and is a change temporary? These are discussion prompts for the clinical team, not instructions for patients to adjust treatment themselves.
A patient holding an older packet at home should be able to connect it with the current plan. If two names appear to describe the same treatment, or an old supply conflicts with new instructions, the person needs a route to clarification. Asking questions is part of reconciliation, not evidence that the patient has failed to listen.
Give the handover an owner
For a team reviewing its process, a useful exercise is to follow one fictional discharge from bedside to community pharmacy. Identify who verifies the history, who resolves conflicting orders, who explains the final list and who receives it next. Then ask what happens if that person is unavailable.
AHRQ's discharge improvement project brings reconciliation together with patient-centred education and checks after discharge. It offers a helpful systems perspective: the point of leaving hospital is not necessarily the point at which every difficulty becomes visible. A medicine that cannot be obtained, or instructions that are unclear at home, needs a response.
Local services can make that response concrete by providing a contact, a follow-up arrangement and an explicit way to raise an unresolved question. These suggestions require adaptation to staffing, access and local clinical policies. A new checklist should clarify accountability rather than add a signature with no action behind it.
Measure understanding as well as completion
Audit can begin by asking whether reconciliation happened, but should also examine what it achieved. Were discrepancies resolved? Was the updated plan available to the next service? Could the patient explain the agreed changes in their own words? These are editorial prompts for improvement work, not a validated scoring instrument.
A small review of actual handovers can reveal where a process loses meaning. Teams should protect patient confidentiality and examine patterns without turning every difficulty into individual blame. The aim is a dependable route from an accurate history to a usable plan.
For patients and caregivers, the practical message is to keep an updated medicines list, bring uncertainties to a pharmacist or clinician and avoid making changes based on conflicting paperwork alone. For professionals, the larger lesson is that reconciliation ends with a shared decision communicated clearly, not merely with matching text.
Sources: AHRQ MATCH toolkit; WHO: Medication safety in transitions of care (2019); AHRQ: Improving hospital discharge.
Editorial review: 20 October 2026. Educational explainer based on the cited sources; no original interviews or individual medical advice.
Image: healthcare staff discussing a file, used as illustrative handover photography. The people pictured are models and are not identified as participants in reported research or a particular clinical handover. Photo: RDNE Stock project / Pexels, used under the Pexels License.
Clinical Care
View more
A new US indication for Jemperli (dostarlimab-gxly) brings an organ-preserving approach into the rectal-cancer conversation. The FDA granted accelerated approval on October 19 for previously untreated stage II or III disease with dMMR or MSI-H tumors, confirmed by an authorized test. This is a small, biologically defined group: the agency estimates roughly 3% of locally advanced rectal cancers have these features. The approval does not extend to every rectal cancer. A different pathway, with follow-up still essential In the 154-patient AZUR-1 study, almost three-quarters had avoided surgery, radiotherapy and chemotherapy after a median follow-up exceeding two years. Longer observation is needed to establish how durable the benefit is and how often cancer returns. Dostarlimab can also trigger severe or fatal immune reactions against healthy tissues. Avoiding conventional treatment does not remove the need for specialist care. The practical shift is a more individual discussion of tumor testing, treatment goals and surveillance. Accelerated approval makes an option available while the sponsor continues collecting evidence of lasting clinical benefit. FDA approval and evidence
After the smoke clears, wildfire survivors may still need lung-health follow-up
Women express interest in trials—but few report receiving an invitation
Diet during antibiotics: a transplant study puts the hospital menu under scrutiny
A mobile clinic can remove the journey to a hospital. Whether it can also make treatment easier to sustain is a different question. A new trial led by Steven Shoptaw and Nabila El-Bassel puts both questions into view, with findings that deserve attention without a victory-lap headline. Published on 4 November in JAMA Psychiatry, HPTN 094 compared two ways of connecting people who inject drugs with HIV prevention and opioid-use-disorder services. The mobile-clinic group experienced fewer deaths over a year. Yet the intervention did not significantly improve the trial's main measures of medication use. Both findings matter. The comparison was more demanding than no care The study enrolled 409 adults without HIV in Houston, Los Angeles, New York City, Philadelphia and Washington, D.C. Participants had opioid use disorder, were not receiving medication for it when enrolled, and were willing to consider treatment. They were randomly assigned to one of two approaches. For 26 weeks, the intervention group received peer navigation plus integrated services through a mobile medical unit. These included oral HIV pre-exposure prophylaxis, known as PrEP, addiction medication and limited clinical and supportive services. The comparison group also received peer navigation, connecting people with existing community services. That active comparison is important. The trial tested the extra contribution of bringing services together on a vehicle when navigation was already available. It cannot be read as mobile clinics versus abandonment, or as a test of whether peer support has value. A striking result with a small event count Four deaths were confirmed among 203 people assigned to the mobile intervention, compared with 13 among 206 assigned to community-service navigation. The reported hazard ratio was 0.29, the basis for the widely publicised 71% relative reduction. Mortality was a secondary outcome, and the researchers say the finding needs replication. The absolute numbers make the result easier to judge. Seventeen deaths across the trial are a serious human loss, but a limited foundation for estimating exactly how large a benefit another programme would deliver. The result supports further investigation; it does not establish a guaranteed effect for every city or patient group. Why the main outcomes still matter At 26 weeks, verified PrEP use was 5.4% in the intervention group and 2.9% in the comparison group. Confirmed addiction-medication use was 14.8% and 10.7%, respectively. Neither difference was statistically significant. The findings therefore leave the original challenge of sustained medication engagement unresolved. It would be misleading to turn the survival result into evidence that the programme succeeded on all its objectives. Equally, a headline declaring the service ineffective would overlook a potentially important signal. Different outcomes answer different questions, and a careful assessment keeps them visible together. Shoptaw and El-Bassel are testing a service model The programme brings a practical research question into the street: what changes when care is available near people facing fragmented services, unstable housing or stigma? Shoptaw at UCLA and El-Bassel at Columbia co-chaired the trial. NIH's account describes accessibility as a central reason for studying this approach. The published protocol also describes planning around local HIV and overdose patterns and available services. A clinic's location is part of its intervention. For readers assessing a similar service, the useful questions concern where it stops, when it operates and whether people can return consistently. What should follow the headline Graymedy's interpretation is that the next step should examine both replication and delivery. A larger or independent evaluation could test the mortality signal. Detailed work on treatment entry, interruptions and return could help explain why medication use remained difficult to sustain. Local teams would also need to assess staffing, referral relationships and continuity after the mobile programme ends. Those are implementation questions raised by the findings, not benefits demonstrated by this trial. A vehicle can provide a place for care; the evidence still has to show which parts of the service change outcomes. For people seeking support, this research is a reason to ask about accessible HIV prevention and addiction services locally. It is not a reason to wait for a particular mobile programme. The study's most useful contribution is a sharper question: how can care reach people repeatedly enough to make a lasting difference? For commissioners, the distinction also affects what to measure next. Counting visits alone would miss whether people remain connected to care. A useful evaluation should specify its clinical outcomes in advance and report practical difficulties alongside improvements, so other communities can judge what is transferable. Sources: HPTN 094 trial, JAMA Psychiatry; HPTN results announcement; NIH, 4 November 2026; Published study protocol. Photo: NIH / study clinic; artwork: Shepard Fairey. Reviewed 5 November 2026. Independently written from public sources; no interview was conducted. General information, not individual medical advice.
How early is too early for a new aortic valve? PROGRESS tests the boundary
Starting CPAP: why a follow-up plan matters as much as the machine
Five-year PHERGain results sharpen the question of who may avoid chemotherapy
Leaving the ward is not the end of treatment Hospital discharge can feel like a milestone, but recovery often continues in a less predictable environment. At home, patients and families become responsible for medicines, appointments, wound checks, mobility and recognizing new symptoms. Instructions delivered during a busy final ward round may be difficult to remember, especially after illness, surgery or a long admission. A safer discharge process begins before the patient reaches the exit and follows through once ordinary life resumes. Why the transition is vulnerable Different clinicians may have changed treatment while a patient was hospitalized. A long-standing tablet might have been stopped, a dose adjusted or a temporary prescription added. The final medication list must reconcile these changes with what is already at home. Problems arise when lists conflict, pharmacy supplies are delayed or patients cannot distinguish a new medicine from an old one. Care teams should confirm not merely what has been prescribed but what the patient will actually take. Making instructions understandable A clear plan explains the reason for admission, what improved, what still needs attention and what recovery should look like. Rather than asking whether someone understands, clinicians can invite them to describe the plan in their own words. This teach-back approach exposes misunderstandings without treating questions as a failure. Written guidance in an appropriate language, accessible formatting and a named contact help patients revisit instructions after fatigue or stress has eased. The importance of the first follow-up For some patients, an early telephone or in-person check can uncover difficulties before they become urgent. A nurse, pharmacist or primary-care clinician may ask whether medicines were obtained, symptoms changed, transport is available and a specialist appointment has been booked. The ideal timing depends on the diagnosis and clinical risk; there is no universal seventy-two-hour rule for everyone. Nevertheless, the opening days at home are a practical opportunity to identify unmet needs. Warning signs must be specific Advice to seek help if symptoms worsen is often too vague. Patients benefit from examples that fit their condition and a clear distinction between routine questions and emergencies. After surgery, this may include concerning bleeding, increasing redness or fever; after a breathing-related admission, it may include worsening breathlessness. Severe chest pain, marked difficulty breathing, new confusion or symptoms suggestive of stroke require emergency assessment. Discharge paperwork cannot replace individualized clinical advice. Recovery includes more than medical tests Someone can be medically ready for discharge yet struggle with stairs, food, transportation or caregiving responsibilities. Financial pressure, limited digital access and low health literacy can make a technically correct care plan difficult to follow. Social workers, occupational therapists, community teams and family caregivers may all be relevant. Good discharge planning therefore assesses the patient's living circumstances and what support is realistically available, not just whether vital signs have stabilized. Connecting hospital and community teams A discharge summary should reach the next clinician promptly and explain key findings, medication changes, pending results and requested follow-up. Pending tests are particularly important: somebody must be responsible for reviewing them and informing the patient when action is needed. When hospital and community records do not communicate well, patients may have to repeat their history or resolve contradictory advice. Shared responsibility and explicit handovers reduce that burden. A practical definition of success The goal is not simply to shorten hospital stays or reduce readmission numbers. It is to make the move home safe, comprehensible and sustainable. Providers can learn from patient calls, medication discrepancies, missed appointments and reports of confusion. Patients should leave knowing what to do today, what to expect next and whom to contact if the plan fails. The best discharge is not a stack of instructions; it is a reliable continuation of care. What families can ask before leaving Before discharge, patients and caregivers can ask for one updated medication list, written warning signs and the contact number for problems arising outside office hours. They can clarify who is booking the next appointment and who will communicate any outstanding results. If equipment, dressing supplies or help moving around is required, arrangements should be confirmed rather than assumed. Families should also know which symptoms call for emergency services instead of a routine callback. These questions are not a substitute for professional judgment; they help translate a hospital plan into a realistic set of actions at home.
Pressure-injury prevention starts with a daily plan for the person
Sudden confusion needs urgent care, even when the patient is quiet
